Phase 3
Completed N=168
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
Source: ClinicalTrials.gov NCT04382924 ↗Enrolled (actual)
168
Serious AEs
7.7%
Results posted
Dec 2021
Primary outcomePrimary: Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients: — 10; 9; 18; 7 Participants — p=<0.025
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19. This Protocol is largely based on the recommendations of the World Health Organization (WHO) R&D Blueprint Clinical Trials Expert Group COVID-19 Therapeutic Trial Synopsis, and associated Master Protocol.
The choice of the primary outcome measure will be determined by a pilot study of the first 150 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients: |
10; 9; 18; 7; 9; 2 | <0.025 sig |
| SECONDARY Status on an Ordinal Scale Assessed Daily While Hospitalized and on Days 15 and 28 in IP Versus Control Group Patients |
4.23; 4.25; 4.25; 4.22; 4.22; 4.29 | — |
| SECONDARY NEWS Assessed Days 3, 5, 8 ,11 Daily While Hospitalized and on Days 15 and 29 in IP Versus Control Group Patients |
4.7; 4.5; 4.5; 4.2; 3.7; 4.4 | — |
| SECONDARY Rate of Mechanical Ventilation in IP Versus Control Group Patients |
5; 2; 4 | — |
| SECONDARY Duration of Mechanical Ventilation (if Applicable) in IP Versus Control Group Patients |
0; 1; 0; 0; 0; 0 | — |
| SECONDARY Duration of Supplemental Oxygen in IP Versus Control Group Patients |
0; 0; 0; 0; 1; 0 | — |
| SECONDARY Time to Return to Room Pressure (SpO2 > 94%) on Room Air |
4; 5; 9 | — |
| SECONDARY Duration in ICU (if Applicable) in IP Versus Control Group Patients |
0; 0; 0; 1; 0; 1 | — |
| SECONDARY Rate of Mortality in IP Versus Control Group Patients |
2; 5; 4 | — |
| SECONDARY Duration of Hospitalization in IP Versus Control Group Patients |
— | — |
| SECONDARY Time to Discharge in IP Versus Control Group Patients |
— | — |
| SECONDARY Effect on the Rate of Change of Partial Pressure of Oxygen (PaO2) and PaO2/FiO2 Ratio Taken at Baseline and Measured Once Daily up to 2 Weeks of Treatment in IP Versus Control Group Patients |
— | — |
Eligibility Criteria
Inclusion Criteria
- Male and female subjects aged ≥18 years of age
- Confirmed coronavirus infection
- Positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for COVID-19 nucleic acid
- Viral gene sequences in respiratory or blood specimens that are highly homologous to COVID-19
- Any other diagnostic test accepted by local regulatory authorities
- Must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (Score of 4 or 5 on WHO Ordinal Clinical Scale)
- Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s)
- Non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s)
- Subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures
Exclusion Criteria
- Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline
- Patients experiencing cerebral hemorrhage or cerebral infarction at baseline
- ALT/AST > 5 times the upper limit of normal; Child-Pugh Score 10 to 15
- Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
- Patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- Patients taking droxidopa
- Pregnant and lactating women and those planning to get pregnant
- Known or suspected allergy to the trial drug or the relevant drugs given in the trial
- Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial
- Know inability of patient to comply with the protocol for the duration of the study
- Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. Participation in observational registry studies is permitted.
Data sourced from ClinicalTrials.gov (NCT04382924). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.